drugset / Trial / NCT04218357

Probenecid as Medication for Alcohol Use Disorder (PROB)

NCT04218357

Phase 1 Completed 35 enrolled Brown University
RandomizedCrossoverQuadruple-blindOther

Summary

The design is a randomized, within-subject, crossover, double-blind, placebo-controlled human alcohol laboratory study with one oral dose of 2g probenecid or placebo administered in two laboratory sessions.

Timeline

Start
2020-12-02
Primary completion
2023-05-16
Completion
2023-05-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Probenecid Small molecule 2 g Oral